All In MedTech

Device Trial Radar · NCT07279142

Efficacy and Safety of 7 Millimeters Vaginal Radiofrequency in Overactive Bladder

Last checked: Nov 19, 2026Latest source record: Dec 12, 2025 (this record)Source: ClinicalTrials.govMethods & limitations

Not yet recruiting

Status

Not yet recruiting

Enrollment

48

Planned (sponsor's estimate)

Start

Dec 16, 2025

Primary completion

Nov 13, 2026

Study completion Dec 24, 2026

Sponsor

Lead sponsor
IRCCS San RaffaeleAcademic, hospital or other
Sponsor type
Academic, hospital or other
Collaborators
University of Campania Luigi Vanvitelli
First posted
Dec 12, 2025

More device trials from this sponsor

Design

Study type
Interventional
Phase
Not applicable (typical for device studies)
Allocation
Non randomized
Model
Parallel
Masking
None
Primary purpose
Treatment
FDA-regulated device
No
Who can join
Female only, from 18 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

The investigator hypothesizes that controlled delivery of low heat (45-50 Centigrade) to the sub-detrusor and detrusor muscle can ablate the autonomic nerve endings and control overactive bladder symptoms without causing significant damage to the surrounding structures. Low heat in such a manner is below urethral sensation and enables office treatment. The transvaginal approach is non-invasive and improves overactive bladder (OAB) symptoms and patients' quality of life. The investigator believes that the RF administration results could be equal or better for first-line treated patients compared to pharmacological refractory patients.

Conditions

  • Overactive Bladder (OAB)
  • Incontinence, Urge

Interventions

  • RadiofrequencyDevice

    According to the study protocol, eligible subjects will receive one treatment within 3 weeks of screening. After one month, if there is no satisfactory result, a second treatment will be administered, and after another month, the patient will be evaluated. If there is still no end point, a third treatment will be given. It should be noted that the second and third treatments will only be performed if there is no satisfactory result after the previous treatment. Treatment area: Treatment area will include vaginal canal. Treatment Procedure: * Subjects receive HYPNOS treatment with device using radiofrequency (RF). Treat vaginal canal at the depth starting from approximately 3.5cm from introitus to the distal end of vagina. Radially the treatment area is from 9 to 3 o'clock. * Patient should empty bladder prior to treatment * Position patient in lithotomy position * Set energy to levels well tolerated by the subject. Suggested settings: Burst Mode 7mm, 1 pass.

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Improvement of 40% in the Overactive Bladder Symptoms Bother Questionnaire Score Short Form from the baseline scoreTime frame: From enrollment to 12 weeks after last treatment

Locations

1 site in 1 country. Site status is shown where the registry gives one.

  • IRCCS Ospedale San Raffaele

    Milan, Italy, Italy

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.